Cyplasin Biomedical Ltd Announces Japanese Patent for its Antitumor Protein(27 May 2008) Cyplasin Biomedical Ltd announced that its Japanese Patent application Nr Hei 9-516992 has been granted. The claims cover the characterization of a cytotoxic protein from the mucus of the sea hare Aplysia punctata and its use to treat cancer."It is ...
Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin(06 Nov 2007) Cyplasin Biomedical Ltd today announced that its U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants" has been granted as US patent Number US ...
Cyplasin-SC Enters Next Phase of Efficacy Animal Testing(09 Oct 2007) In recent third party validated cell based laboratory tests, Cyplasin-SC(TM) has shown a unique toxicity to many tumor cells, including human melanoma cells. However normal human cells are not affected by Cyplasin-SC(TM) at concentrations used to ...
Top
